(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth - 2‘Inoculation’ helps people spot political deepfakes, study finds
- 3Why this Tennessee special election has the 'whole world' watching
- 4After toilet and email issues, Artemis II astronauts fire engine to head for the moon
- 5Instructions to Boost Your True capacity with a Brain research Degree
- 'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- Ways to track down the Right Criminal Legal counselor
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- US FDA grants market authorization to six on! PLUS nicotine pouch products
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- Where You Could Sleep With Snorlax in Japan, From MIMARU’s Pokémon Rooms to Grand Hyatt Tokyo’s Limited Pokémon Suite
